» Articles » PMID: 28752037

Retention of Poloxamer-based Hydrogels for Vaginal Application in Mouse and Rat Models

Overview
Publisher Elsevier
Specialty Pharmacology
Date 2017 Jul 29
PMID 28752037
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

The purpose of this study is to evaluate the retention capabilities of poloxamer-based hydrogels for vaginal application with nonoxinol-9 as the model drug. Two hydrogel formulations, which contained 18% poloxamer 407 plus 1% poloxamer 188 (GEL1, relative hydrophobic) or 6% poloxamer 188 (GEL2, relative hydrophilic), were compared with respect to the rheological properties, hydrogel erosion and drug release. The vaginal retention capabilities of these hydrogel formulations were further determined in two small animal models, including drug quantitation of vaginal rinsing fluid in mice and isotope tracing with Tc in rats. The two formulations exhibited similar phase transition temperatures ranging from 27 to 32 °C. Increasing the content of poloxamer 188 resulted in higher rheological moduli under body temperature, but slightly accelerated hydrogel erosion and drug release. When compared , GEL1 was eliminated significantly slower in rat vagina than GEL2, while the vaginal retention of these two hydrogel formulations behaved similarly in mice. In conclusion, increases in the hydrophilic content of formulations led to faster hydrogel erosion, drug release and intravaginal elimination. Rats appear to be a better animal model than mice to evaluate the hydrogel for vaginal application.

Citing Articles

O2L-001, an innovative thrombolytic to evacuate intracerebral haematoma.

Thiebaut A, Louet E, Ianszen M, Guichard M, Hanley D, Gaudin C Brain. 2023; 146(11):4690-4701.

PMID: 37450572 PMC: 10629768. DOI: 10.1093/brain/awad237.


Investigating the Targeting Power to Brain Tissues of Intranasal Rasagiline Mesylate-Loaded Transferosomal In Situ Gel for Efficient Treatment of Parkinson's Disease.

ElShagea H, Makar R, Salama A, Elkasabgy N, Basalious E Pharmaceutics. 2023; 15(2).

PMID: 36839855 PMC: 9967009. DOI: 10.3390/pharmaceutics15020533.


Calcitermin-Loaded Smart Gels Activity against : A Preliminary In Vitro Study.

Bellotti D, DAccolti M, Pula W, Huang N, Simeliere F, Caselli E Gels. 2023; 9(2).

PMID: 36826335 PMC: 9957098. DOI: 10.3390/gels9020165.


Quercetin Loaded Cationic Solid Lipid Nanoparticles in a Mucoadhesive In Situ Gel-A Novel Intravesical Therapy Tackling Bladder Cancer.

Shawky S, Makled S, Awaad A, Boraie N Pharmaceutics. 2022; 14(11).

PMID: 36432718 PMC: 9695231. DOI: 10.3390/pharmaceutics14112527.


Recent progress of Bioinspired Hydrogel-based delivery system for endometrial repair.

Dong R, Ma S, Zhao X, Wang B, Roy M, Yao L Front Bioeng Biotechnol. 2022; 10:1013217.

PMID: 36159661 PMC: 9503822. DOI: 10.3389/fbioe.2022.1013217.


References
1.
Mayol L, Quaglia F, Borzacchiello A, Ambrosio L, La Rotonda M . A novel poloxamers/hyaluronic acid in situ forming hydrogel for drug delivery: rheological, mucoadhesive and in vitro release properties. Eur J Pharm Biopharm. 2008; 70(1):199-206. DOI: 10.1016/j.ejpb.2008.04.025. View

2.
Chang J, Oh Y, Choi H, Kim Y, Kim C . Rheological evaluation of thermosensitive and mucoadhesive vaginal gels in physiological conditions. Int J Pharm. 2002; 241(1):155-63. DOI: 10.1016/s0378-5173(02)00232-6. View

3.
Owen D, Katz D . A vaginal fluid simulant. Contraception. 1999; 59(2):91-5. DOI: 10.1016/s0010-7824(99)00010-4. View

4.
Liu Y, Zhu Y, Wei G, Lu W . Effect of carrageenan on poloxamer-based in situ gel for vaginal use: Improved in vitro and in vivo sustained-release properties. Eur J Pharm Sci. 2009; 37(3-4):306-12. DOI: 10.1016/j.ejps.2009.02.022. View

5.
Aka-Any-Grah A, Bouchemal K, Koffi A, Agnely F, Zhang M, Djabourov M . Formulation of mucoadhesive vaginal hydrogels insensitive to dilution with vaginal fluids. Eur J Pharm Biopharm. 2010; 76(2):296-303. DOI: 10.1016/j.ejpb.2010.07.004. View